Most recently, exciting positive data from the study arm of sotorasib in combination with carboplatin and pemetrexed for KRAS G12C-mutant advanced NSCLC in the ongoing, phase 1b, CodeBreaK 101, global clinical trial have further endorsed the approach to repositioning sotorasib with novel therapeutic combinations into earlier lines of therapy within the treatment paradigm (44). This evidence concerns the gene KRAS and non-small cell lung carcinoma.